Core Points - Duori Pharmaceutical announced on September 30 that it received a notification from its controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., regarding a potential change in company control [1] - The company has applied for a trading suspension starting from September 29, 2025, with an expected duration of no more than two trading days [1] - As of the announcement date, the parties involved are actively advancing the transaction, but no formal agreement has been signed, leading to uncertainty about the resumption of trading on October 9, 2025 [1] - To ensure fair information disclosure and protect investor interests, the company has applied for an extension of the trading suspension, which is expected to last no more than three additional trading days [1]

Core Viewpoint - Duorui Pharmaceutical is facing significant challenges, including a potential change in control, declining revenue from its core product, and increasing financial burdens due to acquisitions. The company is exploring new growth avenues while grappling with a deteriorating financial situation [1][2][3][4][5][6][7]. Group 1: Control Change - Duorui Pharmaceutical's controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., is planning a change in control, which may lead to a shift in the company's actual controller [2][7]. - The stock was suspended from trading on September 29, 2025, with an expected suspension period of no more than three trading days [2][1]. - As of now, no formal agreements have been signed regarding the control change, and the outcome remains uncertain [2][7]. Group 2: Financial Performance - Duorui Pharmaceutical's revenue has significantly declined since its listing in 2021, with a projected revenue drop of nearly 50% by 2024 compared to its peak [3][4]. - The company reported a revenue of 1.07 billion yuan in the first half of 2025, a year-on-year decrease of 29.13%, and a net loss of 42.5 million yuan, which is a 1197.26% increase in losses compared to the previous year [4]. - The core product, sodium acetate Ringer's injection, has seen a drastic revenue decline, with sales dropping from 465 million yuan in 2021 to an estimated 12 million yuan in 2024 [3][4]. Group 3: Product Challenges - The sodium acetate Ringer's injection, which accounts for nearly 50% of the company's main business revenue in 2024, has faced declining sales due to policy changes such as medical insurance cost control and centralized procurement [3][4]. - The company has acknowledged the risk of having a single product structure, which has contributed to its financial struggles [3]. Group 4: Acquisition Strategy - To counteract declining revenues, Duorui Pharmaceutical has pursued acquisitions, including Hubei Xinchengda Chemical Co., Ltd. and Sichuan Duorui Pharmaceutical Co., Ltd., to diversify its revenue streams [5][6]. - In the first half of 2025, Hubei Xinchengda contributed 33.18 million yuan to the company's revenue, accounting for 31% of total revenue [5]. - The acquisition of Sichuan Duorui involved a significant financial commitment, leading to increased management, financial, and research expenses [6]. Group 5: Financial Burden - The company's financial obligations have increased, with total liabilities reaching 754 million yuan and an asset-liability ratio of 52.01% as of June 2025, up from 23.37% at the end of 2023 [6]. - To finance acquisitions, Duorui Pharmaceutical's subsidiary applied for a merger loan of up to 300 million yuan, with the company providing a guarantee [6].

Core Points - Duori Pharmaceutical (301075.SZ) is actively advancing its transaction discussions, with no formal agreement signed yet [1] - The company anticipates that it will not resume trading on October 9, 2025, due to uncertainties surrounding the transaction [1] - To ensure fair information disclosure and protect investor interests, the company has applied for a continued trading suspension, expected to last no more than three trading days [1]

Core Viewpoint - Duori Pharmaceutical (301075) announced on September 30, 2025, that it received a notification from its controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., regarding a potential change in company control, which may lead to a change in the controlling shareholder and actual controller [1] Group 1 - The company is currently in discussions regarding the overall plan for the control change, and no formal agreements have been signed yet [1] - As a result of the ongoing negotiations, the company anticipates that it will not be able to resume trading on October 9, 2025, at market opening [1] - The company has applied to the Shenzhen Stock Exchange for an extension of its stock suspension, which is expected to last no more than three trading days [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) is currently in negotiations regarding a transaction, with no formal agreement signed yet, leading to an expected continuation of stock suspension until at least October 9, 2025 [1] Summary by Relevant Sections - **Transaction Status** - The parties involved are actively advancing the transaction, but the overall plan is still under negotiation [1] - No formal agreement has been reached as of the announcement date [1] - **Stock Suspension** - The company anticipates that it will not resume trading on October 9, 2025, at the market opening [1] - Due to the uncertainties surrounding the transaction, the company has applied for an extension of the stock suspension, which is expected to last no more than three trading days [1]

关于筹划控制权变更进展暨继续停牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司 证券代码：301075 证券简称：多瑞医药 公告编号：2025-076 鉴于上述事项存在不确定性，为保证公平信息披露，维护投资者 利益，避免公司股价异常波动，根据《深圳证券交易所上市公司自律 监管指引第 6 号——停复牌》的相关规定，经公司向深圳证券交易所 申请，公司股票（证券代码：301075，证券简称：多瑞医药）自 2025 年 10 月 9 日（星期四）上午开市起继续停牌，预计停牌时间不超过 3 个交易日。 公司将根据上述事项的进展情况，严格按照有关法律法规的规定 和要求履行信息披露义务。待上述事项确定后，公司将及时发布相关 公 告 并 申 请 复 牌 。 公 司 指 定 信 息 披 露 媒 体 为 巨 潮 资 讯 网 （www.cninfo.com.cn），公司所有信息均以在上述指定媒体刊登的信 息为准。敬请投资者关注后续公告，并注意投资风险。 特此公告。 西藏多瑞医药股份有限公司 董事会 控股股东西藏嘉康时代科技发展有限公司、实际控制人邓 ...

Core Viewpoint - Three listed companies, Duori Pharmaceutical, Asia-Pacific Pharmaceutical, and Zhonghuan Environmental Protection, announced on the same day that they are planning changes in control, which may lead to changes in their controlling shareholders and actual controllers [1] Group 1: Duori Pharmaceutical - Duori Pharmaceutical's major shareholder, Tibet Jiakang Times Technology Development Co., is planning a change in control, which may lead to a change in the company's controlling shareholder and actual controller [2] - The company has experienced continuous revenue decline from 2022 to 2024, which may be a reason for the planned change in control [2] - Duori Pharmaceutical's revenue for the first half of 2025 was 107 million yuan, a year-on-year decline of 29.13%, with a net loss of 42.5 million yuan, compared to a loss of 3.27 million yuan in the same period last year [3] Group 2: Asia-Pacific Pharmaceutical - Asia-Pacific Pharmaceutical's major shareholder, Ningbo Fubang Holdings Group, is also planning a change in control, with specific transaction plans and agreements still under discussion [4] - The company has faced continuous revenue decline, with a net profit of -48.86 million yuan for the first half of 2025, a year-on-year decrease of 524.31% [5] - Asia-Pacific Pharmaceutical's revenue for the first half of 2025 was 152 million yuan, a year-on-year decrease of 31.48%, attributed to centralized procurement and intensified market competition [5]

扬子晚报网9月29日讯(记者范晓林薄云峰)9月28日晚间，多瑞医药（301075）、亚太药业（002370）和中环环保（300692）等多家A股公司披露筹划控制 权变更事项。冠中生态（300948）则披露控股股东拟变更为深蓝财鲸。 | | | | 多瑞医药 | | + Q 11 | | | --- | --- | --- | --- | --- | --- | --- | | | | | 301075 创 ■ ▽ | | | | | 注册制 | | 盈利状态:已盈利 表决权:无差异 | | | | | | 40.08 | | 停牌 0.00 0.00% | | | | | | 行业 | | 医药 -0.94% > | | | | | | 今开 0.00 | | 最高 | 0.00 | 成交量 | O | | | 40.08 昨收 | | 最低 | 0.00 | 成交额 | O | | | 市值(1 | | 32.06亿 换手 | 0.00% | 高原 TM | 与损 | | | 停牌 | | 盘后量 | O | 营高额 | | 0 | | 分时 五日 | | 日K | 周Ｋ | 月K | 周期 (0) | | ...

多瑞医药表示，鉴于上述事项尚在筹划中，存在不确定性。为保证公平信息披露，避免公司股价异常波 动，维护广大投资者利益，根据《深圳证券交易所上市公司自律监管指引第6号——停复牌》相关规 定，经公司向深圳证券交易所申请，公司股票（股票简称：多瑞医药，股票代码：301075）自2025年9 月29日（星期一）上午开市起停牌，预计停牌时间不超过2个交易日。 多瑞医药表示，目前各方尚未签署正式协议，正就具体交易方案、协议等相关事项进行论证和磋商，具 体情况以各方签订的正式协议为准。 中国经济网北京9月29日讯 多瑞医药(301075.SZ)昨日发布公告称，公司于2025年9月26日收到公司控股 股东西藏嘉康时代科技发展有限公司、实际控制人邓勇的通知，其正在筹划公司控制权变更相关事宜， 该事项可能导致公司控股股东、实际控制人发生变更。 （责任编辑：马欣） ...

Core Viewpoint - Duori Pharmaceutical (301075) is planning a change in control, leading to a temporary suspension of trading starting September 29, with an expected duration of no more than two trading days [1] Company Summary - The controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., and the actual controller, Deng Yong, are in discussions regarding the change of control [1] - No formal agreements have been signed yet, and discussions on specific transaction plans and agreements are ongoing [1] - The final implementation and outcome of the transaction remain uncertain, and investors are advised to pay attention to subsequent announcements [1]